Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting

Alterity Therapeutics ( (AU:ATH) ) has shared an announcement.

Alterity Therapeutics said its chief medical advisor, Vanderbilt neurologist Daniel Claassen, will deliver a late-breaking oral presentation at the American Academy of Neurology Annual Meeting in Chicago on April 21. The talk will focus on ATH434’s disease-modifying signal in Multiple System Atrophy as measured by the MuSyCA composite scale, underscoring growing clinical evidence for the company’s lead asset as it prepares for a pivotal Phase 3 trial and seeks to strengthen its position in the rare neurodegenerative disease arena.

The upcoming AAN presentation highlights ATH434’s potential to alter the course of MSA, a rare and rapidly progressive condition with limited treatment options. For Alterity, showcasing Phase 2 data in a high-profile neurology forum may enhance scientific credibility, support future regulatory and partnering discussions, and increase visibility among clinicians and investors closely watching developments in novel therapies for movement disorders.

The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative conditions, particularly Multiple System Atrophy and related parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a randomized, placebo-controlled Phase 2 trial and positive results in an open-label Phase 2 study in advanced MSA, supported by a broader discovery platform targeting neurological disease pathology.

Average Trading Volume: 5,614,265

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$97.88M

Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.